Apicell Therapeutics announced on the 12th that it has signed a joint research and development and license agreement with Proaptech for next-generation protein degradation drug candidates.


The core of this agreement is that both companies will combine their differentiated technologies to jointly develop new drug candidates based on LYTAC (Lysosome Targeting Chimera). Apicell Therapeutics will provide its 'eTPD' design technology, which precisely targets disease-related proteins, while Proaptech will apply its proprietary platform 'SelecAll™' technology, which enables the precise conjugation of drugs or functional molecules to proteins. LYTAC refers to next-generation targeted protein degradation (TPD) technology, which selectively degrades cell membrane proteins or secreted extracellular proteins that cause disease.

Apicell Therapeutics and Proaptech to Jointly Develop Next-Generation Protein Degradation Drugs Targeting Cancer and Autoimmune Diseases View original image

Apicell Therapeutics' 'eTPD (extracellular Targeted Protein Degradation)' is a technology designed to selectively target and remove disease-related proteins located outside the cell. Proaptech's 'SelecAll™' is a platform based on non-natural amino acid insertion technology, which enables the precise incorporation of artificial amino acids—ones not found in nature—at specific sites within proteins, allowing for exact site-specific attachment of drugs or functional molecules. Through this collaboration, the two companies expect to finely engineer the structure of LYTAC candidates, thereby enhancing both their stability and therapeutic effect.


According to the market research firm Grand View Research, the global targeted protein degradation (TPD) market is expected to grow to approximately 5 trillion won by 2033. In fact, large-scale joint research and license agreements are increasingly taking place in the global market, especially as major pharmaceutical companies such as Novartis, Eli Lilly, and Merck intensify competition to secure next-generation TPD platforms.


The LYTAC technology, which both companies are developing new drug candidates with, is also a type of TPD technology that is drawing attention in the industry. Whereas conventional protein degradation technologies mainly target intracellular proteins, LYTAC is differentiated by its ability to selectively remove disease-related proteins located on the cell membrane or outside the cell. This opens up new possibilities for the development of therapeutics in challenging areas such as solid tumors and autoimmune diseases, which have traditionally been difficult to treat with conventional drugs.


With this agreement, Apicell Therapeutics has expanded its research and development capabilities, previously focused on cell and gene therapies, into the field of next-generation antibody-based drugs. Proaptech, in turn, will broaden the application of its protein conjugation platform by applying it to actual drug pipelines. The two companies plan to leverage continued collaboration to gain a technological edge in the next-generation antibody therapeutics market.


Seongsu Park, CEO of Apicell Therapeutics, stated, "Proaptech's advanced platform is a key technology that can enhance the completeness of the next-generation protein degradation drugs that Apicell has been pursuing. By combining the strengths of both companies, we will rapidly secure innovative new drug candidates that go beyond the limitations of existing therapeutics."


Jonghaeng Cho, CEO of Proaptech, commented, "Proaptech has been conducting LYTAC research targeting specific molecules based on the SelecAll™ platform. Through this collaboration, we look forward to fully applying our platform technology to the development of next-generation protein degradation drugs and building a globally competitive drug pipeline together with Apicell Therapeutics."


Meanwhile, Apicell Therapeutics is a biotech company jointly established by Daewoong Pharmaceutical and the UK-based Avacta, developing next-generation cell and gene therapies by combining mesenchymal stem cell and antibody mimetic protein (Affimer) technologies. Recently, the company has expanded its R&D focus to include antibody-based drugs and protein degradation technologies.



Proaptech is a bio-venture company that owns the 'SelecAll™' platform, which enables site-specific protein conjugation using non-natural amino acids. This technology allows for precise bonding of drugs or functional molecules to specific sites on proteins, enabling the manufacture of homogeneous drugs with higher conjugation yields compared to existing methods, as well as realizing high efficacy and stability. Based on this, Proaptech is expanding its research into next-generation antibody-based anticancer drugs and protein degradation therapeutics.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing